Susquehanna International Group
BBIO icon

Susquehanna International Group’s BridgeBio Pharma BBIO Stock Holding History

Susquehanna International Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$177M Sell
2,384,600
-285,700
-11% -$20.7M 0.02% 566
2025
Q4 		$204M Sell
2,670,300
-308,100
-10% -$20.2M 0.02% 531
2025
Q3 		$155M Buy
2,978,400
+41,300
+1% +$2.01M 0.02% 647
2025
Q2 		$127M Sell
2,937,100
-168,400
-5% -$6.12M 0.02% 631
2025
Q1 		$107M Sell
3,105,500
-400,100
-11% -$13.5M 0.02% 621
2024
Q4 		$96.2M Buy
3,505,600
+367,600
+12% +$9.5M 0.01% 738
2024
Q3 		$79.9M Buy
3,138,000
+146,800
+5% +$3.85M 0.01% 774
2024
Q2 		$75.8M Buy
2,991,200
+1,985,600
+197% +$54.3M 0.01% 730
2024
Q1 		$31.1M Buy
1,005,600
+261,000
+35% +$8.88M 0.01% 1376
2023
Q4 		$30.1M Buy
744,600
+103,700
+16% +$3.11M 0.01% 1407
2023
Q3 		$16.9M Sell
640,900
-203,400
-24% -$5.77M ﹤0.01% 1928
2023
Q2 		$14.5M Buy
844,300
+603,100
+250% +$9.07M ﹤0.01% 2063
2023
Q1 		$4M Buy
241,200
+186,200
+339% +$2.17M ﹤0.01% 3796
2022
Q4 		$419K Buy
55,000
+31,000
+129% +$297K ﹤0.01% 8302
2022
Q3 		$239K Sell
24,000
-247,100
-91% -$2.57M ﹤0.01% 10386
2022
Q2 		$2.46M Buy
271,100
+112,600
+71% +$942K ﹤0.01% 4463
2022
Q1 		$1.61M Sell
158,500
-666,700
-81% -$6.84M ﹤0.01% 5967
2021
Q4 		$13.8M Buy
825,200
+761,900
+1,204% +$32.2M ﹤0.01% 2287
2021
Q3 		$2.97M Sell
63,300
-20,400
-24% -$1.09M ﹤0.01% 4984
2021
Q2 		$5.1M Sell
83,700
-21,300
-20% -$1.22M ﹤0.01% 4006
2021
Q1 		$6.47M Buy
105,000
+26,700
+34% +$1.75M ﹤0.01% 3450
2020
Q4 		$5.57M Buy
78,300
+65,500
+512% +$3.16M ﹤0.01% 3249
2020
Q3 		$480K Sell
12,800
-294,300
-96% -$9.26M ﹤0.01% 7768
2020
Q2 		$10M Buy
307,100
+105,900
+53% +$3.23M ﹤0.01% 2134
2020
Q1 		$5.83M Buy
+201,200
New +$6.24M ﹤0.01% 2384

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's BBIO Position: Q1 2026 in Review

Susquehanna International Group reduced its BridgeBio Pharma (BBIO) stake by 18% in Q1 2026, selling an estimated $6.41M and leaving 398,943 shares worth $29.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1755.

Susquehanna International Group first reported a position in BBIO in Q3 2019 and has held it in 26 quarters since. The position peaked at $37.3M in Q4 2025. 458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Susquehanna International Group held 398,943 shares of BridgeBio Pharma worth $29.6M as of Q1 2026.
  • Susquehanna International Group sold 88,433 BridgeBio Pharma shares in Q1 2026, an estimated $6.41M.
  • BridgeBio Pharma made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #1755 holding.
  • Susquehanna International Group first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 26 quarters since.
  • Susquehanna International Group's BridgeBio Pharma position peaked at $37.3M in Q4 2025.
  • 458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.